The subgroup in AML with mutated chromatin, RNA-splicing genes, or both showed extremely poor survival, whereas the group with TP53 mutations showed somewhat better outcomes than in a previous paper, although the number of patients with TP53 mutations was much smaller (1.5%) than that reported in a NK-AML population [8]. The gene discussed is TP53; the disease is acute myeloid leukemia.